Journey Medical Corp (DERM) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 4, 2024, provides preliminary estimated unaudited financial results for the three- and nine-month periods ended September 30, 2024. The filing also announces the U.S. Food and Drug Administration (FDA) approval of Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults.
Key Financial Metrics
| Metric | 3 Months Ended Sept 30, 2024 | 9 Months Ended Sept 30, 2024 |
|---|---|---|
| Total Net Product Revenues | $14.6 million | $42.5 million |
| Gross Margin | 63.9% | Filing text does not provide a clear value |
| R&D Expenses | $0.8 million | $9.6 million |
| SG&A Expenses | $11.4 million | $30.4 million |
| Net Income (Loss) | $(2.4) million | $(16.2) million |
| Cash Balance (Q3 End) | $22.5 million | Filing text does not provide a clear value |
Material Changes vs. Prior Period
- Revenue: Three-month revenue decreased to $14.6 million from $15.3 million in the prior year period. Nine-month revenue decreased to $42.5 million from $44.4 million.
- Profitability: Net loss for the three months ended September 30, 2024, was $(2.4) million, a significant decline from net income of $16.8 million in the same period in 2023. This variance is primarily attributed to a one-time $19.3 million payment received from Maruho Co., Ltd. in August 2023 related to an exclusive license grant.
- Expenses:
- R&D: Increased to $9.6 million for the nine-month period (vs. $6.0 million prior year), driven by a $4.1 million FDA filing fee for DFD-29 and a $3.0 million milestone payment to Dr. Reddy's Laboratories, Ltd (DRL).
- SG&A: Increased to $11.4 million for the quarter (vs. $8.6 million prior year) due to a $1.0 million increase in non-cash share-based compensation and costs associated with launch efforts for Emrosi.
Guidance, Outlook, and Material Events
- 2024 Financial Guidance: The company maintains its full-year 2024 guidance:
- Net product revenue: $55-$60 million.
- SG&A expense: $39-$42 million.
- R&D expense: $9-$10 million.
- Emrosi Approval & Milestones: FDA approval of Emrosi triggered a $15.0 million milestone payment obligation to DRL, due within 30 days. Initial U.S. supply is anticipated in late Q1 or early Q2 2025.
- Debt & Liquidity: The FDA approval triggered an obligation to draw the remaining $5.0 million under a credit facility with SWK Funding LLC (increased from $20.0M to $25.0M in July 2024). The company intends to draw this amount in Q4 2024 to fund the milestone payment.
- Fraud Recovery: The company expects to receive approximately $4.4 million in Q4 2024, recovered from a 2021 cybersecurity incident, pursuant to a court order signed in September 2024.
Investor Verification Checklist
- Verify the timing and amount of the $15.0 million milestone payment to DRL and the $5.0 million debt drawdown in Q4 2024.
- Confirm the expected receipt date of the $4.4 million fraud recovery funds.
- Monitor the commercial launch timeline for Emrosi, specifically the availability of initial supply in Q1/Q2 2025.
- Review the impact of the $19.3 million one-time Maruho payment in 2023 on year-over-year profitability comparisons.
- Assess the company's liquidity position post-Q4 debt drawdown and milestone payments.